Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 52

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 52
---
 and commercial considerations

On March 21, 2025, MIRA provided Moore with a detailed forecast of MIRA’s research and development and general administrative expenses through 2027, proforma financials, historical R&D spending analysis, estimated drug prices, market share information, and royalty information, as prepared by MIRA’s Chief Financial Officer and controller. MIRA’s Chief Scientific Advisor provided Moore a presentation, including targeted diseases and a roadmap for all clinical trials and timelines. MIRA’s Chief Executive Officer also had input to all deliverables.

On March 23, 2025, Moore provided MIRA with follow up questions related to diligence. MIRA promptly responded with the requested information.

On March 26, MIRA’s Chief Financial Officer provided responses to the questions asked by Moore.

On April 8, 2025, Moore provided SKNY with follow up questions related to diligence. SKNY promptly responded with the requested information.

On April 9, 2025, Moore provided the parties a preliminary valuation of SKNY.

On April 10, 2025, Moore provided the parties a preliminary valuation of MIRA.

On April 21, 2025, Moore provided a preliminary oral discussion of its valuation results with the management teams of MIRA and SKNY.

On April 22, 2025, Moore provided SKNY’s and MIRA’s management with an initial fairness opinion for the Exchange Ratio and valuation reports of SKNY and MIRA.

On April 30, 2025, MIRA’s board of directors held a meeting to discuss the approval of the Merger Agreement and Exchange Ratio. Moore presented MIRA’s board of directors with an analysis of its determination of MIRA’s and SKNY’s valuations. MIRA’s and SKNY’s management provided a discussion regarding the benefits of the Merger. MIRA’s legal counsel provided a discussion on the potential conflicts of interest involved in the Merger. Following several discussions and questions, MIRA’s board of directors approved the Merger.

On May 22, 2025, Moore provided MIRA with a revised fairness addressing additional details related to SKNY’s business.

| 26 |

Moore Fairness Opinion and Valuation Reports

On March 14, 2025, MIRA retained Moore as financial advisor to MIRA in connection with the Merger. SKNY had previously never been subject to a third-party valuation. Moore was selected due to its global presence, and in particular, its presence in and familiarity with the markets and